BRAF and melanoma: Owing to SREBP1-dependent continuous lipogenesis being a key mechanism of drug resistance induced by the BRAF mutant, simultaneous inhibition of SREBP1 enhances the sensitivity of melanoma [91], which suggests that identifying the mechanism of resistance and then synergistic use of agents will better sensitize and combat tumors.